Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

45.88 -1.41 (-2.99%)
Streaming Delayed Price Updated: 1:56 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 200,984
Open 47.53
Bid (Size) 45.85 (2)
Ask (Size) 45.93 (2)
Prev. Close 47.30
Today's Range 45.80 - 47.70
52wk Range 26.76 - 67.66
Shares Outstanding 48,855,602
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
Via ACCESSWIRE

Performance

YTD
+62.71%
+62.71%
1 Month
-14.44%
-14.44%
3 Month
-17.93%
-17.93%
6 Month
+21.81%
+21.81%
1 Year
+56.44%
+56.44%

More News

Read More
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023
Via ACCESSWIRE
Amphastar Pharma: Q1 Earnings Insights
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
Via ACCESSWIRE
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why
Via Talk Markets
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023
Via ACCESSWIRE
Earnings Outlook For Amphastar Pharma
Via Benzinga
Lilly to Divest BAQSIMI to Amphastar
Via ACCESSWIRE
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
Via ACCESSWIRE
Promising Small Biotech Amphastar Sees Actionable Pullback
Via MarketBeat
Abcam Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) Records 52-Week High Tuesday Morning
Via Investor Brand Network
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
Via ACCESSWIRE
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
Via Investor's Business Daily
Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash
Via Benzinga
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
Via ACCESSWIRE
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.